Modélisation de la décorporation du Pu/am par le dtpa

Modelling Pu/Am decorporation by DTPA. A new tool has been developed to optimize DTPA efficacy as concerns reduction of effective dose after 239 Pu wound. For example, the simulations show, for moderately soluble compounds (type M), a 1/3 decrease of effective dose is obtained after repeated early treatment (24 i.v. for 4 months), whereas a decrease by a factor 5 can be reached if treatments continue for 5 years at 2 week interval. By contrast, for poorly soluble compounds (type S), negligible efficacy is observed after early treatments, and a 3 time decrease of dose is obtained for treatments performed at 2 week interval for 50 years. Some of the hypotheses retained for modelling DTPA decorporation are validated from new experimental data published recently, and structure of a new model which can be applied both to Pu and Am is reported, taking into account urinary and faecal excretion, structure being suitable for different doses of DTPA and using various galenic forms.